Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
Connect Biopharma (NASDAQ: CNTB) has announced it will present four posters at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The presentations focus on their drug candidate rademikibart for treating moderate-to-severe asthma and COPD.
The presentations include studies on: rademikibart's efficacy in COPD-like patients, its effect on blood eosinophil counts, structural properties of the drug's IL-4Rα complex, and rapid improvement in lung function for asthma patients. The company plans to initiate parallel Phase 2 trials in Q2 2025.
Key presenters include Dr. Michael Wechsler and Dr. Raúl Collazo, with sessions covering topics such as asthma and COPD clinical studies, biomarkers in lung disease, and treatment modalities in inflammatory lung diseases.
Connect Biopharma (NASDAQ: CNTB) ha annunciato che presenterà quattro poster al American Thoracic Society (ATS) 2025 International Conference che si terrà a San Francisco dal 18 al 21 maggio 2025. Le presentazioni sono incentrate sul loro candidato farmaco rademikibart per il trattamento dell'asma da moderata a grave e della BPCO.
Le presentazioni includono studi sull'efficacia di rademikibart nei pazienti con caratteristiche simili alla BPCO, il suo effetto sui livelli di eosinofili nel sangue, le proprietà strutturali del complesso IL-4Rα del farmaco e il rapido miglioramento della funzione polmonare nei pazienti asmatici. L'azienda prevede di avviare trial paralleli di Fase 2 nel secondo trimestre del 2025.
I principali relatori saranno il Dr. Michael Wechsler e il Dr. Raúl Collazo, con sessioni che tratteranno temi quali studi clinici su asma e BPCO, biomarcatori nelle malattie polmonari e modalità di trattamento nelle patologie infiammatorie polmonari.
Connect Biopharma (NASDAQ: CNTB) ha anunciado que presentará cuatro pósters en la Conferencia Internacional 2025 de la Sociedad Torácica Americana (ATS) en San Francisco, del 18 al 21 de mayo de 2025. Las presentaciones se centran en su candidato a fármaco rademikibart para el tratamiento del asma moderada a grave y la EPOC.
Las presentaciones incluyen estudios sobre la eficacia de rademikibart en pacientes con características similares a la EPOC, su efecto sobre el recuento de eosinófilos en sangre, las propiedades estructurales del complejo IL-4Rα del fármaco y la rápida mejora de la función pulmonar en pacientes asmáticos. La compañía planea iniciar ensayos paralelos de fase 2 en el segundo trimestre de 2025.
Los principales ponentes incluyen al Dr. Michael Wechsler y al Dr. Raúl Collazo, con sesiones que cubrirán temas como estudios clínicos de asma y EPOC, biomarcadores en enfermedades pulmonares y modalidades de tratamiento en enfermedades pulmonares inflamatorias.
Connect Biopharma (NASDAQ: CNTB)는 2025년 5월 18일부터 21일까지 샌프란시스코에서 열리는 미국 흉부학회(ATS) 2025 국제 학술대회에서 네 편의 포스터를 발표할 예정입니다. 발표 내용은 중등도에서 중증 천식 및 만성 폐쇄성 폐질환(COPD) 치료를 위한 후보 약물 라데미키바트(rademikibart)에 관한 것입니다.
발표 내용에는 COPD 유사 환자에서 라데미키바트의 효능, 혈중 호산구 수에 미치는 영향, 약물의 IL-4Rα 복합체 구조적 특성, 천식 환자의 폐 기능 빠른 개선에 대한 연구가 포함되어 있습니다. 회사는 2025년 2분기에 병행하는 2상 임상시험을 시작할 계획입니다.
주요 발표자는 마이클 웩슬러 박사와 라울 콜라조 박사이며, 세션에서는 천식 및 COPD 임상 연구, 폐 질환의 바이오마커, 염증성 폐 질환 치료법 등의 주제를 다룰 예정입니다.
Connect Biopharma (NASDAQ : CNTB) a annoncé qu'elle présentera quatre posters lors de la Conférence internationale 2025 de l'American Thoracic Society (ATS) à San Francisco, du 18 au 21 mai 2025. Les présentations portent sur leur candidat-médicament rademikibart destiné au traitement de l'asthme modéré à sévère et de la BPCO.
Les présentations comprennent des études sur : l'efficacité de rademikibart chez des patients présentant des caractéristiques proches de la BPCO, son effet sur le nombre d'éosinophiles sanguins, les propriétés structurelles du complexe IL-4Rα du médicament, ainsi que l'amélioration rapide de la fonction pulmonaire chez les patients asthmatiques. La société prévoit de lancer des essais parallèles de phase 2 au deuxième trimestre 2025.
Les principaux intervenants seront le Dr Michael Wechsler et le Dr Raúl Collazo, avec des sessions couvrant des sujets tels que les études cliniques sur l'asthme et la BPCO, les biomarqueurs dans les maladies pulmonaires et les modalités de traitement des maladies inflammatoires pulmonaires.
Connect Biopharma (NASDAQ: CNTB) hat angekündigt, dass es auf der American Thoracic Society (ATS) 2025 International Conference, die vom 18. bis 21. Mai 2025 in San Francisco stattfindet, vier Poster präsentieren wird. Die Präsentationen konzentrieren sich auf ihren Arzneimittelkandidaten rademikibart zur Behandlung von mittelschwerem bis schwerem Asthma und COPD.
Die Präsentationen umfassen Studien zur Wirksamkeit von rademikibart bei COPD-ähnlichen Patienten, dessen Wirkung auf die Blut-Eosinophilenzahl, strukturelle Eigenschaften des IL-4Rα-Komplexes des Medikaments sowie die schnelle Verbesserung der Lungenfunktion bei Asthmapatienten. Das Unternehmen plant, im zweiten Quartal 2025 parallele Phase-2-Studien zu starten.
Zu den Hauptreferenten gehören Dr. Michael Wechsler und Dr. Raúl Collazo. Die Sitzungen behandeln Themen wie klinische Studien zu Asthma und COPD, Biomarker bei Lungenerkrankungen und Behandlungsmethoden bei entzündlichen Lungenerkrankungen.
- Advancing to Phase 2 trials indicates positive development progress
- Multiple clinical applications being explored (both asthma and COPD)
- Preliminary data shows rapid improvement in lung function for asthma patients
- None.
– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation –
– Advancing rapid clinical development plan for rademikibart; expect to initiate parallel Phase 2 trials in 2Q25 –
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the Company will present four posters at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco.
The following abstracts are posted on ATS 2025’s online itinerary planner for registered users:
Title: Efficacy of Rademikibart in COPD-like Patients: Sub-analyses From the Phase 2b Trial in Patients with Moderate-to-Severe Asthma
Presenter: Raúl Collazo, Ph.D.
Session A32: It’s Not Easy Being Wheezy: Asthma and COPD Clinical Studies
Format: Thematic Poster Session
Poster #: P1386
Date and Time: Sunday, May 18, 2025, from 11:30 a.m. – 1:15 p.m. PT
Title: Effect of Rademikibart on Blood Eosinophil Counts in Patients with Asthma: Is There an IL-4Rα Class Effect?
Presenter: Michael Wechsler, M.D.
Session A33: Biomarker Window into Lung Disease
Format: Thematic Poster Session
Poster #: P1515
Date and Time: Sunday, May 18, 2025, from 11:30 a.m. – 1:15 p.m. PT
Title: Optimized Second-generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of Rademikibart Fab-IL-4Rα Complex
Presenter: Raúl Collazo, Ph.D.
Session A34: Winning the Biologic Battle in Asthma and COPD
Format: Thematic Poster Session
Poster #: P1439
Date and Time: Sunday, May 18, 2025, from 11:30 a.m. – 1:15 p.m. PT
Title: Rapid Improvement in Lung Function Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Presenter: Michael Wechsler, M.D.
Session B101: Fixing Barriers: Unlocking Treatment Modalities in Inflammatory Lung Diseases
Format: Poster Discussion Session
Poster #: 1020
Date and Time: Monday, May 19, 2025: Viewing: 2:15 p.m. – 3:00 p.m. PT | Discussion: 3:15 p.m. – 4:15 p.m. PT
Following the presentations, each poster will be available on Connect’s website under the Presentations and Publications section.
About Connect Biopharma and Rademikibart
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV1), observed within one week—and in most cases, within 24 hours via home spirometry.
For more information visit www.connectbiopharm.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the “Act”). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial condition, results of operations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), planned or expected product approval applications or approvals, anticipated milestones, expected data readouts and enrollments, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, and adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we will need expanded or additional trials in order to obtain regulatory approval for our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the PRC, Europe and other jurisdictions; the ability of our current cash and investments position to support planned operations; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; and the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community.
Words such as “aim,” “anticipate,” “believe,” “could,” “expect,” “feel,” “goal,” “intend,” “may,” “optimistic,” “plan,” “potential,” “promising,” “will,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results may differ materially due to the risks and uncertainties inherent in our business and other risks described in our filings with the U.S. Securities and Exchange Commission (the “SEC”). Further information regarding these and other risks is included under the heading “Risk Factors” in our annual and periodic reports filed with the SEC. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date of this presentation. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. Connect Biopharma claims the protection of the safe harbor for forward-looking statements contained in the Act for all forward-looking statements.
This press release discusses product candidates that are under clinical study, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or by any other regulatory agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.
Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
What clinical trials is Connect Biopharma (CNTB) planning for rademikibart in 2025?
How many presentations will CNTB deliver at ATS 2025?
What conditions is rademikibart being developed to treat?
What are the key findings being presented about rademikibart's effectiveness?
